ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LYEL vs RCKT // RETURN ON INVESTED CAPITAL (ROIC)

Lyell Immunopharma Inc. (NASDAQ) VS. Rocket Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: LYEL 1 — RCKT 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LYEL VS. RCKT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LYEL RCKT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -41.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 61.4 45.2 +16.16 LYEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $277.0M $278.8M -$1.8M RCKT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LYEL REV RCKT REV LYEL GROSS % RCKT GROSS % LYEL FCF RCKT FCF
FY 2025 $36.0K $0 — — -$150.8M -$190.5M
FY 2024 $61.0K $0 — — -$162.9M -$215.6M
FY 2023 $130.0K $0 — — -$163.7M -$194.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LYEL // BETA —
RCKT // BETA —